Tuesday, September 20, 2016

Tobira Therapeutics Acquired By Allergan For $1.7B

San Francisco-based Tobira therapeutics, a publicly held biopharmaceuticals firm developing threapy to treat liver disease, has been acquired by Allergan, in a deal worth $1.695 billion. Allergan said it will pay $28.35 per share in cash, and up to $49.84 per share in earn out, for Tobira. Tobira trades on the NASDAQ as TBRA. Tobira is commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. Allergan is based in Dublin, Ireland.